Biocon Ltd. News and Updates

Name: Latest research reports of Biocon Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Biocon Ltd. from all sources in a single place.

Load latest

Biocon Ltd.

03 May 2018, 01:13PM

361.55

1.53%

Biocon shares tank 6% on USFDA observations

Business Line

Shares of Biocon tumbled 6 per cent today as the biotechnology major said the US health regulator had made seven observations after inspecting its s

Number of FII/FPI investors increased from 305 to 333 in Jun 2025 qtr.

Biocon shares fall 5% after US, European regulators issue observations

livemint | 03 May 2018, 10:32AM 1 more

Biocon Ltd.

01 May 2018

361.55

1.53%

The obvious opportunity is biosimilars, says Biocon's Kiran Mazumdar-Shaw

Business Standard

A month ago, Biocon announced that its biosimilar insulin glargine trademarked as Semglee received marketing approval from the European Commission

Biocon Ltd. is trading below its 30 day SMA of 370.0

Biocon Ltd.

30 Apr 2018

361.55

1.53%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues increased 26% YoY to | 1170 crore (I-direct estimate: | 1098 crore) mainly due to 48% YoY growth in Biologics to | 241 crore (I-direct estimate: | 179 crore) and 45% YoY growth in Syngene to | 409 crore (I-direct estimate: | 359 crore). EBITDA margins remained at 20%, however lower than I-direct estimates of 22.0% mainly due to lower gross margins led by change in product mix. EBITDA increased 24% YoY to | 233 crore...

Biocon Ltd. is trading below its 30 day SMA of 370.0

Biocon Ltd.

27 Apr 2018

361.55

1.53%

Biocon Q4 net up 2%; annual profit slides 39% to 372 crore

Business Line

Our Bureau Bengaluru-based biopharma company Biocon posted muted annual results on Friday, as it was faced with continued pricing challenges in the g

Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr

Biocon Q4 results: Good progress on biosimilars, though margins below expectations

Business Today | 27 Apr 2018 1 more

Biocon Ltd.

12 Apr 2018

361.55

1.53%

Biocon jumps to over 1-month high

Business Line

Shares of Biocon jumped as the company's partner Mylan and FKB have signed a deal for arthritis drug in the European Union. Biocon stock rose as much

Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.

Biocon Ltd.

28 Mar 2018

361.55

1.53%

EU, Australia clear Biocon-Mylan biosimilar insulin glargine

Business Line

Biocon on Wednesday said that its co-developed biosimilar insulin glargine Semglee has received marketing approval from the European Commission.Biocon has developed this biosimilar with Myla

Biocon Ltd. has an average target of 367.20 from 5 brokers.

Biocon Ltd.

20 Mar 2018

361.55

1.53%

Biocon sees approvals unlocking $1 billion biosimilar sales

livemint

Three more approvals Biocon now expects this year in the US and Europe would expand its presence in the pioneering field of biosimilars

Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.

USFDA approvals can unlock $1 bn biosimilar business for Biocon in the US

Business Standard | 20 Mar 2018

Biocon Ltd.

07 Mar 2018

361.55

1.53%

Eight Indian women in Forbes billionaires list 2018; Savitri Jindal richest

Business Standard

Biocon chief Kiran Mazumdar-Shaw is the second richest Indian woman

Number of FII/FPI investors increased from 305 to 333 in Jun 2025 qtr.

Biocon Ltd.

26 Feb 2018

361.55

1.53%

I personally feel NHPS has not been thought through fully: Kiran Mazumdar-Shaw

livemint

The National Health Protection Scheme needs to be integrated with primary healthcare to make it viable and sustainable, says the Biocon chairman Kiran Mazumdar-Shaw

Mutual Funds have increased holdings from 8.77% to 15.24% in Jun 2025 qtr.

Biocon Ltd.

23 Feb 2018

361.55

1.53%

Biocon to set up R&D; facility in Hyderabad

Business Line

Biocon, the biopharmaceuticals major, will start an R&D lab of its subsidiary Syngene in Genome Valley, Hyderabad, along with an expansion of its existing API/Intermediates facility. The

Biocon Ltd.'s price crossed above 200Day SMA today

Is Biocon Ltd. worth buying?

726 Votes:

Buy 74.93%

Sell 16.39%

Hold 8.68%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf